Last reviewed · How we verify
Non-adjuvanted QIV
Non-adjuvanted QIV is a Inactivated influenza vaccine Biologic drug developed by Seqirus. It is currently in Phase 3 development for Seasonal influenza prevention in adults.
Non-adjuvanted QIV is a quadrivalent inactivated influenza vaccine that stimulates immune responses against four influenza virus strains without added adjuvant components.
Non-adjuvanted QIV is a quadrivalent inactivated influenza vaccine that stimulates immune responses against four influenza virus strains without added adjuvant components. Used for Seasonal influenza prevention in adults.
At a glance
| Generic name | Non-adjuvanted QIV |
|---|---|
| Sponsor | Seqirus |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated (killed) influenza virus antigens representing two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages. It works by presenting these antigens to the immune system to generate humoral and cellular immune responses, producing antibodies and T-cell immunity against the targeted influenza strains. The non-adjuvanted formulation relies on the inherent immunogenicity of the viral antigens without additional immune-enhancing compounds.
Approved indications
- Seasonal influenza prevention in adults
Common side effects
- Injection site pain or erythema
- Myalgia
- Headache
- Fatigue
- Low-grade fever
Key clinical trials
- A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age (PHASE3)
- Effects of Aging on Primary and Secondary Vaccine Responses (PHASE1)
- Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults (PHASE2)
- Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age (PHASE2)
- A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age (PHASE3)
- Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older (PHASE1, PHASE2)
- Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children. (PHASE3)
- Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine (QIV) in Children Previously Vaccinated in Trial V118_05 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Non-adjuvanted QIV CI brief — competitive landscape report
- Non-adjuvanted QIV updates RSS · CI watch RSS
- Seqirus portfolio CI
Frequently asked questions about Non-adjuvanted QIV
What is Non-adjuvanted QIV?
How does Non-adjuvanted QIV work?
What is Non-adjuvanted QIV used for?
Who makes Non-adjuvanted QIV?
What drug class is Non-adjuvanted QIV in?
What development phase is Non-adjuvanted QIV in?
What are the side effects of Non-adjuvanted QIV?
Related
- Drug class: All Inactivated influenza vaccine drugs
- Manufacturer: Seqirus — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Seasonal influenza prevention in adults